

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

**RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JULY 20, 2018,
AND RETIREMENT AND APPOINTMENT OF DIRECTORS**

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, on July 20, 2018, the Company held its Annual General Meeting (the “**AGM**”) at which all resolutions set out in the notice of the AGM dated June 20, 2018 were duly passed by way of poll.

The Board also announces that Mr. KANG Kai has retired as a non-executive Director and Mr. WANG Qiang has been appointed as an executive Director with effect from the conclusion of the AGM.

Reference is made to the circular (the “**Circular**”) of the Company dated June 20, 2018. Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

RESULTS OF THE AGM

The Board is pleased to announce that at the AGM held at 19/F, Building B, Greenland Center, Chaoyang District, Beijing, the PRC on Friday, July 20, 2018 at 10:30 a.m., all the ordinary resolutions set out in the notice of the AGM (the “Notice”) dated June 20, 2018 (the “Resolutions”) were duly passed by way of poll at the AGM. The poll results in respect of the Resolutions were as follows:

ORDINARY RESOLUTIONS		Number of Shares Voted (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditors for the year ended March 31, 2018.	7,164,733,257 (100.00%)	0 (0.00%)
2.	(a) To elect Mr. WANG Qiang as an executive director of the Company.	7,162,939,357 (99.96%)	2,863,900 (0.04%)
	(b) To re-elect:		
	(i) Mr. SHEN Difan as an executive director of the Company;	7,164,608,357 (99.98%)	1,194,900 (0.02%)
	(ii) Ms. ZHANG Yu as a non-executive director of the Company;	7,161,369,916 (99.94%)	4,445,341 (0.06%)
	(iii) Mr. YAN Xuan as an independent non-executive director of the Company.	7,159,682,979 (99.91%)	6,120,278 (0.09%)
	(c) To authorize the board of directors of the Company to fix the directors’ remuneration.	7,165,483,817 (99.99%)	79,440 (0.01%)
3.	To re-appoint Ernst & Young as the auditor of the Company and to authorize the board of directors to fix their remuneration.	7,158,901,959 (99.90%)	6,901,298 (0.10%)
4.	To grant a general mandate to the directors of Company to issue and allot shares.	6,971,341,525 (97.29%)	194,461,732 (2.71%)
5.	To grant a general mandate to the directors of the Company to repurchase shares.	7,165,563,257 (100.00%)	0 (0.00%)
6.	To approve the addition of the aggregate amount of the shares repurchased as mentioned in resolution no. 5 to the aggregate amount that may be issued and allotted pursuant to resolution no. 4.	6,973,448,287 (97.32%)	192,354,970 (2.68%)

ORDINARY RESOLUTIONS		Number of Shares Voted (%)	
		For	Against
7.	To approve the grant of a mandate authorizing the directors of the Company to grant awards of options and/or restricted share units (the “RSUs”) pursuant to the share award scheme adopted by the Company on November 24, 2014 (the “Share Award Scheme”) in respect of a maximum number of the underlying new shares that is equivalent to 3 per cent. of the shares in issue as at the date of passing of this resolution during the period from the date of passing this resolution until the earlier of (a) conclusion of the Company’s next annual general meeting, (b) the end of the period within which the Company is required by any applicable law or its bye-laws to hold its next annual general meeting and (c) the date on which this resolution is varied or revoked by an ordinary resolution of the shareholders of the Company in general meeting (the “Applicable Period”) and to allot, issue and deal with shares underlying the options and/or RSUs granted pursuant to the Share Award Scheme during the Applicable Period as and when such options and/or RSUs vest.	6,984,540,656 (97.47%)	181,262,601 (2.53%)

Notes:

- (1) The full text of the resolutions is set out in the Notice.
- (2) As at the date of the AGM:
 - (a) the total number of Shares in issue was 9,846,760,037;
 - (b) a total of 133 grantees under the Share Award Scheme held 19,417,283 Shares (which represents proximately 0.197% of the total issued Shares as at the date of the AGM) upon exercising and vesting of the Options and the RSUs (as applicable). Such grantees include two Directors, namely Mr. Wang Lei and Mr. Kang Kai, holding 2,271,500 and 74,000 Shares, respectively, as a result of the vesting of RSUs granted to them, and directors of the subsidiaries of the Company, holding 6,168,161 Shares in total as a result of the exercising and vesting of Options and RSUs (as applicable) granted to them. All such 133 grantees are required to abstain from voting on Resolution no. 7 in relation to the 2018 Share Award Mandate. Except as disclosed herein and the extent that the Directors are aware having made all reasonable enquiries, none of the Directors and directors of the Company’s subsidiaries, who are also Participants under the Share Award Scheme who have been granted any Share Awards, holds any Share;

- (c) the total number of shares entitling the Shareholders to attend and vote for or against the Resolutions (other than Resolution no.7) at the AGM was 9,846,760,037 and the total number of share entitling the Shareholders to attend and vote for or against Resolution no.7 was 9,827,342,754; and
 - (d) the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the AGM was nil.
- (3) Tricor Secretaries Limited, the Company's branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the resolutions.

As more than 50% of the total votes were cast in favour of each of resolutions no. 1 to no. 7, all of resolutions no. 1 to no. 7 were duly passed as ordinary resolutions of the Company.

RETIREMENT OF DIRECTOR

As disclosed in the Circular, Mr. KANG Kai has retired from office as a non-executive Director with effect from the conclusion of the AGM. Mr. KANG Kai has confirmed that in relation to his retirement, he has no disagreement with the Board and there is no matter which needs to be brought to the attention of the Stock Exchange or the Shareholders.

The Board takes this opportunity to express its gratitude to Mr. KANG Kai for his valuable contribution and support during his tenure.

APPOINTMENT OF DIRECTOR

Reference is made to the Circular and the announcement of the Company dated June 19, 2018. The Board is pleased to announce that Mr. WANG Qiang has been appointed as an executive Director with effect from the conclusion of the AGM.

The biography of Mr. Wang is set out below:

Mr. WANG Qiang, 41, joined the Group as chief financial officer since September 2017, and is responsible for the Group's financial management, capital markets, internal controls and procurement. He currently serves as a director of certain subsidiaries of the Company and also acts as a consultant to Alibaba Group Holding Limited (the ultimate controlling Shareholder of the Company, and the American depository shares of which are listed on the New York Stock Exchange) and its subsidiaries. Prior to joining the Group, Mr. Wang was the vice president of Intime Retail (Group) Company Limited ("Intime") since January 2014 and chief financial officer of Intime since July 2014, and was responsible for the company's financial management, cost control, investment development, legal affairs, information management, capital markets and investor relations. He had been assistant to president of Intime since February 2012 and general

manager of financial management department of Intime since March 2008, responsible for Intime's financial management. Prior to joining Intime, he took various financial management positions in Veolia Water, Asia Pacific and ABB China from 1999 to 2008.

Mr. Wang was also a director of Wuhan Department Store Group Co., Ltd. (SZSE: 00501) from December 2013 to June 2018. He graduated from the accounting department of Renmin University of China in 1999 and obtained a bachelor's degree in economics.

As at the date of this announcement, Mr. Wang was interested in 4,000,000 Shares and 1,200,000 Shares, respectively, underlying the Options and Restricted Share Units granted to him in accordance with the Share Award Scheme, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed, as at the date of this announcement, Mr. Wang did not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed, Mr. Wang did not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years and did not hold any other position with the Company or other members of the Group.

Mr. Wang shall enter into an appointment letter with the Company in relation to such proposed appointment for a term of one year commencing from the date of the AGM. The term of such appointment shall be renewable for a one-year period upon expiry of each term, subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the provisions of the bye-laws of the Company.

In addition to the Share Awards granted to him in accordance with the Share Award Scheme as aforementioned, Mr. Wang is entitled to receive a salary of RMB96,300 per month as chief financial officer of the Group. His remuneration was determined with reference to his experience and prevailing market rates. Mr. Wang will not receive remuneration from the Company for his position as executive Director.

After the retirement of Mr. KANG Kai and the appointment of Mr. WANG Qiang being effective and as at the date of this announcement, the Board comprises eight Directors, of whom (i) two are executive Directors, namely Mr. SHEN Difan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Ms. ZHANG Yu; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
SHENG DIFAN
Chief Executive Officer and Executive Director

Hong Kong, July 20, 2018

As at the date of this announcement, the Board comprises eight Directors, of whom (i) two are an executive Directors, namely Mr. SHEN Difan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Ms. ZHANG Yu; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.